Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 70/100

Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024 Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...

Key Takeaway: Insmed Incorporated announced it will release its first-quarter 2024 financial results on May 9, 2024. A conference call for investors will also take place at 8:00 a.m. ET the same day to discuss these results and provide a business update. Insmed, known for its therapies for serious and rare diseases, is headquartered in Bridgewater, New Jersey, and has a promising pipeline of investigational therapies. This is part of its ongoing mission to improve patient outcomes in challenging health conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed is set to release its first-quarter 2024 financial results, indicating continuous progress.
  • The company is focused on transforming the lives of patients with serious and rare diseases.
  • It has a strong pipeline of investigational therapies targeting serious unmet medical needs.

Full Press Release Details

BRIDGEWATER, N.J. , April 25, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its first-quarter 2024 financial results on Thursday, May 9, 2024 .
Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday , May 9, 2024, to discuss the financial results and provide a business update.
Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing access code 7862189. The call will also be webcast live on the Company's website at www.insmed.com .
A replay of the conference call will be accessible approximately 1 hour after its completion through June 8, 2024 , by dialing (800) 770-2030 (U.S.) and (609) 800-9909 (international) and referencing access code 7862189. A webcast of the call will also be archived for 90 days under the Investor Relations section of the Company's website at www.insmed.com .
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States , Europe , and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey , with additional offices and research locations throughout the United States , Europe , and Japan . Visit www.insmed.com to learn more.
Bryan Dunn Executive Director, Investor Relations Insmed (646) 812-4030 [email protected]
Eleanor Barisser Associate Director, Investor Relations Insmed (718) 594-5332 [email protected]
Mandy Fahey Executive Director, Corporate Communications Insmed (732) 718-3621 [email protected]
SOURCE Insmed Incorporated

21 %

Frequently Asked Questions

When will Insmed release its Q1 2024 financial results?

Insmed will release its first-quarter 2024 financial results on May 9, 2024.

How can I participate in the Insmed conference call?

Participants can join by dialing (888) 210-2654 for U.S. or (646) 960-0278 internationally.

What is Insmed's focus as a biopharmaceutical company?

Insmed aims to transform lives with therapies for serious and rare diseases.

Where can I find the archived conference call?

The archived call will be available on Insmed's website for 90 days.

What types of therapies is Insmed developing?

Insmed is developing therapies for neutrophil-mediated inflammatory diseases and rare lung disorders.

Last updated: Apr 25, 2024